Trials / Completed
CompletedNCT06016231
Clinical Outcomes of Patients with a Light Adjustable Lens (LAL) in At Least One Eye
Clinial Outcomes of Bilateral Pseudophakic Patients with a Light Adjustable Lens (LAL) Implanted in At Least One Eye
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (actual)
- Sponsor
- Bucci Laser Vision Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To collect data on bilateral pseudophakic patients implanted with the RxSight Light Adjustable Lens (LAL) in at least one eye
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Light Adjustable Lens | The Light Adjustable Lens (LAL) is a posterior chamber, UV absorbing, three-piece, foldable, photoreactive silicone intraocular lens with a squared posterior optic edge intended to be implanted in the capsular bag following phacoemulsification. Selective exposure of the implanted RxSight LAL using the Light Delivery Device (LDD) to deliver a spatially profiled UV light produces modifications in the lens curvature resulting in a spherical or spherocylindrical power change post-operatively. A subsequent lock-in exposure is delivered to the implanted LAL to stabilize the lens power. |
Timeline
- Start date
- 2023-08-15
- Primary completion
- 2023-12-31
- Completion
- 2023-12-31
- First posted
- 2023-08-29
- Last updated
- 2024-10-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06016231. Inclusion in this directory is not an endorsement.